Headquartered in New Haven, CT Fiscal year ends December NYSE: BHVN biohaven.com
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies across immunology, neuroscience, oncology, and obesity. The company operates multiple proprietary drug development platforms, including its MoDE and TRAP extracellular protein degradation platforms targeting autoimmune diseases by selectively removing disease-driving antibodies, Kv7 ion channel modulation for epilepsy (opakalim), myostatin/activin pathway inhibition for obesity and neuromuscular diseases (taldefgrobep alfa), and an antibody-drug conjugate (ADC) oncology portfolio including FGFR3-directed and TROP2-directed candidates. Biohaven has no commercial revenue and is funded through equity and debt financings as it advances multiple programs toward pivotal and registrational studies. Updated
It’s always a good idea to pay close attention to analyst upgrades. Often, they’re influenced by (1) company fundamentals, such as financial health, future growth, and even meetings with management; (2) industry…
Pre-Market Stock Futures: Futures are trading higher as we prepare to wrap up one of the worst trading weeks in some time. The song remains the same as the rotation out of…
Pre-Market Stock Futures: Futures are trading lower on Wednesday after an ADP report showing job losses, following a stellar day across Wall Street on Tuesday. All of the major indices finished the…
Pre-Market Stock Futures: The futures are trading modestly higher as Thanksgiving Eve has finally arrived. After a slow start on Tuesday, all the major indices began to rally by noon and finished…
Carl Icahn has made another huge bet, boosting his stake in a utility infrastructure company. It was not the only big insider buying though.
Initial public offerings and a secondary offering inspired insiders to pick up some shares of these biotech companies and others.
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Biohaven, Edwards Lifesciences, Enphase Energy, Halliburton, Invesco, Liberty Energy, Mattel, Netflix, Permian Resources, Range Resources, Roblox, Synchrony Financial and Visa.
Wednesday’s additional top analyst upgrades and downgrades were on Ally Financial, Baker Hughes, Biohaven, Biogen, Bumble, Canopy Growth, Corning, Discover Financial Services, Match, Roku and more.
Friday's additional top analyst upgrades and downgrades were on Applied Materials, Dick’s Sporting Goods, Foot Locker, HP, Meta Platforms, Occidental Petroleum and more.
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including Biohaven Pharmaceutical, SmileDirectClub, Squarespace and Victoria’s Secret.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of therapies across immunology, neuroscience, oncology, and obesity.
The Wall Street consensus 12-month price target for BHVN is $21.27. BHVN price prediction →
